GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Sarepta Therapeutics Inc (SRPT) [hlAlert]

Rating:
Buy SRPT
up 50.14 %

Sarepta Therapeutics Inc (SRPT) upgraded to Buy with price target $30 by Canaccord Genuity

Posted on: Wednesday,  May 20, 2015  10:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Buy Sarepta Therapeutics Inc (NASDAQ: SRPT) on 05/20/2015, when the stock price was $24.13. Since
then, Sarepta Therapeutics Inc has gained 50.15% as of 01/19/2016's recent price of $36.23.
If you would have followed this Canaccord Genuity's recommendation on SRPT, you would have gained 50.14% of your investment in 244 days.

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI's NEUGENE-based ESPRIT technology will initially be applied to potential treatments for Duchenne muscular dystrophy.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/20/2015 10:25 AM Buy
None
24.13 30.00
as of 8/27/2015
1 Week up  11.61 %
1 Month up  10.86 %
3 Months up  136.48 %
1 YTD up  50.14 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/4/2014 10:25 AM Hold
None
28.67 27.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy